Get the Stockscreener App
2.78
1.77%
-0.05
After Hours:
2.76
-0.02
-0.72%
Protalix BioTherapeutics Inc. stock is traded at $2.78, with a volume of 1.64M.
It is down -1.77% in the last 24 hours and down -4.47% over the past month.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase IIa clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.
See More
Previous Close:
$2.83
Open:
$2.83
24h Volume:
1.64M
Relative Volume:
1.49
Market Cap:
$223.57M
Revenue:
$63.63M
Net Income/Loss:
$10.62M
P/E Ratio:
55.60
EPS:
0.05
Net Cash Flow:
$-8.64M
1W Performance:
-7.64%
1M Performance:
-4.47%
6M Performance:
+80.52%
1Y Performance:
+17.30%
1-Day Range:
$2.66
$2.84
1-Week Range:
$2.66
$3.045
52-Week Range:
$1.32
$3.19
Protalix BioTherapeutics Inc. Stock (PLX) Company Profile
Name
Protalix BioTherapeutics Inc.
Sector
Industry
Phone
972 4 988 9488
Address
2 Snunit Street, Science Park PO Box 455, Karmiel
Compare PLX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLX
Protalix BioTherapeutics Inc.
|
2.78 | 227.59M | 63.63M | 10.62M | -8.64M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-08-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-17-17 | Reiterated | Rodman & Renshaw | Buy |
| Apr-04-16 | Initiated | Rodman & Renshaw | Buy |
| Apr-23-15 | Upgrade | Jefferies | Hold → Buy |
| Nov-12-14 | Reiterated | R. F. Lafferty | Buy |
| Jan-24-14 | Initiated | R. F. Lafferty | Buy |
| May-02-12 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-02-12 | Reiterated | Oppenheimer | Outperform |
| Apr-30-12 | Downgrade | Auriga | Buy → Hold |
| Oct-13-11 | Initiated | Morgan Joseph | Hold |
| Mar-17-11 | Downgrade | WBB Securities | Strong Buy → Buy |
| Nov-09-10 | Reiterated | Oppenheimer | Outperform |
| Oct-14-10 | Reiterated | UBS | Buy |
| Dec-02-09 | Reiterated | Hapoalim | Outperform |
| Sep-22-09 | Initiated | Canaccord Adams | Buy |
| Sep-02-09 | Initiated | Hapoalim | Outperform |
| Dec-01-08 | Reiterated | Oppenheimer | Outperform |
| Mar-11-08 | Initiated | UBS | Buy |
| Nov-20-07 | Initiated | CIBC Wrld Mkts | Sector Outperform |
View All
Protalix BioTherapeutics Inc. Stock (PLX) Latest News
Retail Trends: Should I invest in Protalix BioTherapeutics Inc before earningsJuly 2025 Selloffs & Reliable Volume Spike Alerts - baoquankhu1.vn
MAK Capital Group (PLX) reports 4,649,599 shares, a 5.8% stake - Stock Titan
Published on: 2026-03-01 19:16:31 - baoquankhu1.vn
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
Protalix BioTherapeutics Reports First Quarter 2025 Financial an - GuruFocus
PLX Should I Buy - Intellectia AI
Protalix BioTherapeutics (NYSE:PLX) Shares Down 0.7%Time to Sell? - MarketBeat
Protalix Biotherapeutics Hits New 52-Week High of $3.19 - Markets Mojo
Is Protalix BioTherapeutics Inc a top pick in the sectorTrade Ideas & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Published on: 2026-02-21 10:08:13 - baoquankhu1.vn
What is the PEG ratio of Protalix BioTherapeutics Inc.Earnings Trend Report & Safe Entry Trade Signal Reports - mfd.ru
Should I invest in Protalix BioTherapeutics Inc. before earnings2025 AllTime Highs & Risk Controlled Stock Pick Alerts - mfd.ru
Swing Trade: Will Protalix BioTherapeutics Inc benefit from rising consumer demandMarket Activity Recap & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Why Protalix BioTherapeutics Inc. stock could be next big winnerEarnings Summary Report & Safe Entry Momentum Stock Tips - mfd.ru
Shorts Report: Will Protalix BioTherapeutics Inc. (DE) stock outperform benchmarks2025 Macro Impact & Daily Risk Controlled Trade Plans - mfd.ru
Will Protalix BioTherapeutics Inc. benefit from rising consumer demandGap Down & Short-Term Trading Alerts - mfd.ru
Will Protalix BioTherapeutics Inc. benefit from government policy2025 Price Momentum & Weekly Momentum Stock Picks - mfd.ru
Protalix Highlights Positive EMA Opinion on Elfabrio Dosing - TipRanks
Protalix BioTherapeutics, Inc. Announces Positive CHMP Opinion for Elfabrio® - TradingView
Why retail investors favor Protalix BioTherapeutics Inc. stockTrade Analysis Report & Risk Adjusted Swing Trade Ideas - mfd.ru
Fabry Disease Market Hits USD 1.7 Billion in 2024, Set for Strong Expansion Across the 7MM Through 2034 | DelveInsight - Barchart.com
RSI Check: Is Protalix BioTherapeutics Inc currently under institutional pressureWeekly Market Summary & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Aug Patterns: Should I invest in Protalix BioTherapeutics Inc before earnings2025 Technical Patterns & Consistent Return Strategy Ideas - baoquankhu1.vn
Protalix Biotherapeutics Forms Golden Cross, Signaling Bullish Breakout Ahead - Markets Mojo
What is Zacks Small Cap’s Forecast for PLX FY2025 Earnings? - Defense World
Protalix BioTherapeutics (NYSE:PLX) Trading Up 6.2%Here's Why - MarketBeat
Reviewing Protalix BioTherapeutics (NYSE:PLX) & JATT Acquisition (NYSE:JATT) - Defense World
Protalix BioTherapeutics (PLX) Price Target Decreased by 12.00% to 11.22 - Nasdaq
PLX: CHMP Delivers Positive Opinion - Research Tree
Protalix says EU panel recommended a new dosing regimen for Fabry disease therapy - MSN
A March Decision That Could Change Protalix BioTherapeutics Outlook - Seeking Alpha
Protalix's New Dosing Regimen Recommended for Approval - Intellectia AI
Protalix (PLX) Surges 14% on Positive EMA Panel Opinion for Elfa - GuruFocus
Protalix rises as EU backs new dosing for Elfabrio (PLX:NYSE) - Seeking Alpha
Protalix (PLX) Gains Positive EMA Opinion for New Elfabrio Dosage - GuruFocus
Protalix Wins EMA Panel Backing for New Elfabrio Dosing - TipRanks
Protalix wins EU panel backing for expanded dosing of Fabry disease drug - Proactive financial news
Protalix BioTherapeutics Announces Positive CHMP Opinion for Elfabrio Dosing Regimen - TradingView
CHMP backs new Elfabrio regimen for Protalix (NYSE: PLX) patients - Stock Titan
Chiesi Global Rare Diseases and Protalix BioTherapeutics - GlobeNewswire
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU - GlobeNewswire
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU - Yahoo Finance
Market movers: Verizon, Sandisk, Protalix Biotherapeutics, American Express… - Proactive financial news
Is Protalix BioTherapeutics Inc. a strong candidate for buy and holdJuly 2025 Retail & Weekly Return Optimization Alerts - mfd.ru
Aug Summary: Should I invest in Rentokil Initial plc Depositary Receipt before earningsJuly 2025 Movers & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Winners Losers: Can Protalix BioTherapeutics Inc sustain its profitabilityM&A Rumor & Consistent Profit Trading Strategies - baoquankhu1.vn
Can Protalix BioTherapeutics Inc. lead its sector in growthPortfolio Performance Summary & Weekly Breakout Watchlists - bollywoodhelpline.com
Analyst Calls: Is PCG.PRH stock influenced by commodity prices2025 Volatility Report & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Aug Selloffs: What is Protalix BioTherapeutics Inc. s 5 year growth outlookJuly 2025 Earnings & Daily Profit Focused Screening - bollywoodhelpline.com
SQZ Biotechnologies (NYSE:SQZ) vs. Protalix BioTherapeutics (NYSE:PLX) Critical Review - Defense World
Protalix, Secarna in agreement to develop rare kidney disorder therapies - MSN
Protalix BioTherapeutics Inc. Stock (PLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):